| Identification | Back Directory | [Name]
ACY-1215 | [CAS]
1316214-52-4 | [Synonyms]
ACY 63
CS-583
ACY-1215
Rocilinostat
Ricolinostat
ACY-1215/ACY1215
Rocilinostat, >=99%
Rocilinostat (ACY-1215)
Ricolinostat (ACY-1215)
ACY-1215 (Rocilinostat)
Parathyroid hormone - Shire
RICOLINOSTAT;ACY1215;ACY 1215
1316214-52-4 ACY1215,ROCILINOSTAT
ROCILINOSTAT; ACY1215; ACY 1215;RICOLINOSTAT
7-{[2-(Diphenylamino)pyrimidin-5-yl]formamido}-N-hydroxyheptanamide
2-(Diphenylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]-5-pyrimidinecarboxamide
2-(DiphenylaMino)-N-(7-(hydroxyaMino)-7-oxoheptyl)pyriMidine-5-carboxaMide
5-Pyrimidinecarboxamide, 2-(diphenylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]-
N-[7-(hydroxyamino)-7-oxoheptyl]-2-(N-phenylanilino)pyrimidine-5-carboxamide
2-(Diphenylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]-5-pyrimidinecarboxamide ACY 1215 | [Molecular Formula]
C24H27N5O3 | [MDL Number]
MFCD22666356 | [MOL File]
1316214-52-4.mol | [Molecular Weight]
433.5 |
| Chemical Properties | Back Directory | [Melting point ]
189 - 191°C | [density ]
1.239±0.06 g/cm3(Predicted) | [storage temp. ]
-20°C Freezer | [solubility ]
DMSO (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
9.47±0.20(Predicted) | [color ]
White to Off-White |
| Hazard Information | Back Directory | [Description]
ACY-1215 is an inhibitor of histone deacetylase 6 (HDAC6; IC50 = 5 nM).1 It is at least 10-fold less active against other HDACs in enzymatic assays. ACY-1215 shows synergistic activity with the proteasome inhibitor bortezomib (Item No. 10008822) against multiple myeloma (MM) cells, inducing protracted endoplasmic reticulum stress and apoptosis.1,2 ACY-1215 combined with proteasome inhibitors suppresses tumor growth and increases survival in mice with MM and mantle cell lymphoma xenografts.2,1,3 A multicenter phase I trial examining ACY-1215 combined with the E3 ligase inhibitor lenalidomide (Item No. 14643) and dexamethasone (Item No. 11015) in multiple myeloma found inhibition of HDAC6 in vivo.4 ACY-1215 also diminishes liver cyst development and fibrosis in a rat model of polycystic liver disease.5 | [Uses]
This compound acts as a selective HDAC-6 (histone deacetylase) inihibitor. HDAC is linked to the transcription of DNA in cancers, including multiple myeloma (MM). | [Definition]
ChEBI: N-[7-(hydroxyamino)-7-oxoheptyl]-2-(N-phenylanilino)-5-pyrimidinecarboxamide is a pyrimidinecarboxylic acid. | [target]
HDAC6 |
|
|